The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ozmen, L.
Right arrow Articles by Garotta, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ozmen, L.
Right arrow Articles by Garotta, G.

The Journal of Immunology, Vol 150, Issue 7 2698-2705, Copyright © 1993 by American Association of Immunologists


ARTICLES

Mouse soluble IFN gamma receptor as IFN gamma inhibitor. Distribution, antigenicity, and activity after injection in mice

L Ozmen, G Gribaudo, M Fountoulakis, R Gentz, S Landolfo and G Garotta
F. Hoffmann-La Roche Ltd, Pharmaceutical Research-New Technologies, Basel, Switzerland.

With the purpose to use a soluble receptor as an IFN gamma antagonist in vivo, we assessed the immunogenicity, the half-life, the bioavailability, and the activity of the soluble receptor after injection into mice. No significant immunogenicity was detected after multiple chronic injections of mouse (Mo)IFN gamma-R or injections of MoIFN gamma-R in emulsion with CFA. Pharmacokinetic experiments using radiolabeled MoIFN gamma-R revealed that the half-life of the soluble MoIFN gamma-R is 3 h in the blood and 6 h in the lymphoid organs. When the MoIFN gamma-R protein was traced by the capacity of the animal sera to displace the binding of radiolabeled MoIFN gamma-R from affinity purified rabbit anti-MoIFN gamma-R antibodies, a blood half-life of 1 h was determined. Finally, the capacity of the injected receptor to bind and neutralize the IFN gamma-mediated antiviral activity was assessed in vivo. Treatment with IFN-gamma or IFN-alpha A/D protected the mice from the lethal infection with encephalomyocarditis virus. Mice treated with MoIFN-gamma-R neutralized the protective effect of IFN-gamma.


This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
K. C. Chadha, J. L. Ambrus Jr., W. Dembinski, and J. L. Ambrus Sr.
Interferons and Interferon Inhibitory Activity in Disease and Therapy
Experimental Biology and Medicine, April 1, 2004; 229(4): 285 - 290.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Adachi and M. Tsujimoto
FEEL-1, a Novel Scavenger Receptor with in Vitro Bacteria-binding and Angiogenesis-modulating Activities
J. Biol. Chem., September 6, 2002; 277(37): 34264 - 34270.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Adachi and M. Tsujimoto
Characterization of the Human Gene Encoding the Scavenger Receptor Expressed by Endothelial Cell and Its Regulation by a Novel Transcription Factor, Endothelial Zinc Finger Protein-2
J. Biol. Chem., June 28, 2002; 277(27): 24014 - 24021.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C.-S. Han, Y. Chen, T. Ezashi, and R. M. Roberts
Antiviral activities of the soluble extracellular domains of type I interferon receptors
PNAS, May 3, 2001; (2001) 111139598.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
T. Murase, N. Kume, H. Kataoka, M. Minami, T. Sawamura, T. Masaki, and T. Kita
Identification of Soluble Forms of Lectin-Like Oxidized LDL Receptor-1
Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 715 - 720.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
A. M. Gronowski, D. M. Hilbert, K. C. F. Sheehan, G. Garotta, and R. D. Schreiber
Baculovirus Stimulates Antiviral Effects in Mammalian Cells
J. Virol., December 1, 1999; 73(12): 9944 - 9951.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
F. Nicoletti, P. Zaccone, R. Di Marco, M. Lunetta, G. Magro, S. Grasso, P. Meroni, and G. Garotta
Prevention of Spontaneous Autoimmune Diabetes in Diabetes-Prone BB Rats by Prophylactic Treatment with Antirat Interferon-{gamma} Antibody
Endocrinology, January 1, 1997; 138(1): 281 - 288.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. C. Tan, S. Braun, H. Rong, R. DiGiacomo, E. Dolphin, S. Baldwin, S. K. Narula, P. J. Zavodny, and C.-C. Chou
Characterization of Recombinant Extracellular Domain of Human Interleukin-10 Receptor
J. Biol. Chem., May 26, 1995; 270(21): 12906 - 12911.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Fountoulakis, C. Mesa, G. Schmid, R. Gentz, M. Manneberg, M. Zulauf, Z. Dembic, and G. Garotta
Interferon [IMAGE] Receptor Extracellular Domain Expressed as IgG Fusion Protein in Chinese Hamster Ovary Cells
J. Biol. Chem., February 24, 1995; 270(8): 3958 - 3964.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C.-S. Han, Y. Chen, T. Ezashi, and R. M. Roberts
Antiviral activities of the soluble extracellular domains of type I interferon receptors
PNAS, May 22, 2001; 98(11): 6138 - 6143.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.